TrkC expression caused by immunoreactivity was observed in 62.5% of melanomas of various stages, and its expression significantly increased 58% of melanoma that progressed from in situ lesions, 91% of papillary dermal invasions, 57% of melanomas which invaded the deeper dermis, and 31% of melanomas which metastasized to sites other than the compound nevi [25]. Here, NTRK3 is linked to melanoma.